KBC Group
DNA icon

KBC Group’s Ginkgo Bioworks DNA Stock Holding History

KBC Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,113
Closed -$18K – 1741
2025
Q1 		$18K Hold
3,113
– – ﹤0.01% 1874
2024
Q4 		$31K Buy
+3,113
New +$26.7K ﹤0.01% 1827
2024
Q2 		– Sell
-644
Closed -$30K – 1864
2024
Q1 		$30K Hold
644
– – ﹤0.01% 1768
2023
Q4 		$44K Hold
644
– – ﹤0.01% 1612
2023
Q3 		$47K Buy
+644
New +$51.5K ﹤0.01% 1490

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

KBC Group's DNA Position: Q2 2025 in Review

KBC Group sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 3,113 shares — an estimated $18K sold.

KBC Group first reported a position in DNA in Q3 2023 and held it in 5 quarters. The position peaked at $47K in Q3 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • KBC Group reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • KBC Group sold 3,113 Ginkgo Bioworks shares in Q2 2025, an estimated $18K.
  • KBC Group first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 5 quarters.
  • KBC Group's Ginkgo Bioworks position peaked at $47K in Q3 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.